Nevertheless, prospective validation is warranted to confirm its utility in guiding targeted therapies (e.g., granulocyte colony-stimulating factor in neutropenic sepsis or albumin supplementation in hypoalbuminemia). This evidence concerns the gene CSF3 and Hypoalbuminemia.